Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adaptive phase 2b/3 trial of zelpultide alfa for prevention of bronchopulmonary dysplasia in high-risk preterm neonates
MOH_2025-11-27_015502Phase 3Recruiting
- Sponsor
- Airway Therapeutics
- Start
- Jul 2025
- Modality
- Replacement Enzymes → Therapeutic Enzymes → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of zelpultide alfa in bronchopulmonary dysplasia (BPD) (5 arms), sponsored by Airway Therapeutics. Primary endpoints: Dose-selection efficacy and safety in part 1 and Incidence of grade 2 or grade 3 bronchopulmonary dysplasia and death in part 2. Started Jul 2025; status: recruiting.
02
Drugs
zelpultide alfa
03
Conditions
bronchopulmonary dysplasia (BPD)
Beyond the preview
Go deeper on MOH_2025-11-27_015502.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2025-11-27_015502.